Global Non-invasive Prenatal Testing Market to Post a CAGR Surpassing 17% During 2016-2020: Technavio

LONDON--()--According to the latest market study released by Technavio, the global non-invasive prenatal testing (NIPT) market is expected to grow at a CAGR of more than 17% during the forecast period.

This research report titled ‘Global Non-invasive Prenatal Testing Market 2016-2020’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.

Array comparative genomics hybridization is an emerging, cutting-edge, non-invasive DNA-based technology for prenatal identification of many genetic abnormalities. Some companies such as Thermo Fisher Scientific and Perkin-Elmer are developing array comparative genomics hybridization technology-based NIPT products.

Request a sample report:

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Based on testing product, the report categorizes the global non-invasive prenatal testing market into the following segments:

Global NIPT market segmentation by testing product 2015

MaterniT21 Plus test 36.34%
NIFTY test 21.31%
Harmony test 18.27%
Bambni test 8.58%
Verifi test 6.43%
Panorama test 6.05%
PrenaTest 3.02%

Source: Technavio

The top three revenue generating segments for the global NIPT market are discussed below:

Global NIPT market for MaterniT21 Plus test

The MaterniT21 Plus laboratory-developed test is the most advanced NIPT that helps detect the gender of the fetus and diagnose abnormalities in chromosomes 21, 18, and 13 in singleton and higher-order multiple pregnancies. The test involves blood samples for analysis, which can be performed with the 10 weeks of gestation and results are obtained within seven days. Healthcare providers recommend this test in cases of pregnancies in advanced maternal age, personal or family history of chromosomal abnormalities, fetal ultrasound abnormality suggestive of chromosomal abnormalities, and positive serum screening test.

“The MaterniT21 PLUS test also offers the enhanced sequencing series to analyze select microdeletions and additional trisomies when observed. Among other tests, it offers the most comprehensive information available,” says Srinivas Sashidhar, a lead analyst at Technavio for research on life science research tools.

Global NIPT market for NIFTY test

The NIFTY test is a safe, simple, non-invasive prenatal technique used to detect certain genetic disorders such as Down, Edward, and Patau syndromes in developing fetuses of 10 weeks. Using the latest genetic sequencing technology, the NIFTY test has over 99% accuracy for the three most common trisomy conditions present during birth. The test offers higher accuracy than traditional screening tests such as amniocentesis and has no risks of miscarriage. It also offers optional testing for other genetic conditions such as deletion syndromes and sex chromosome aneuploidies.

Global NIPT market for Harmony test

The Harmony test introduced by Ariosa Diagostics helps analyze maternal serum for the fetal DNA. The test identifies:

  • 99% of the fetuses with trisomy 21 (Down syndrome)
  • 97% of fetuses with trisomy 18 (Edward syndrome)
  • 92% of fetuses with trisomy 13 (Patau syndrome)

“The test has a lower rate of false positive results than combined first trimester screening. This has led many people to shift toward this test from CVS or amniocentesis to confirm high-risk results. The test can be performed after 10 weeks of gestation in both single and twin pregnancies, as well as in-vitro fertilization-based pregnancies,” says Srinivas.

Verifi, MaterniT21, and iGene tests are major substitutes to the Harmony test. However, this test costs about USD 580, which is low compared with others. It also has favorable reimbursement in Europe and Australia. This has led to its higher adoption worldwide, particularly in many specialized obstetric ultrasound services-based medical facilities in Australia.

The top vendors highlighted by Technavio’s research analysts in this report are:

  • BGI Genomics
  • Illumina
  • LifeCodexx
  • Natera
  • Sequenom

Browse Related Reports:

Do you need a report on a market in a specific geographical cluster or country but can’t find what you’re looking for? Don’t worry, Technavio also takes client requests. Please contact with your requirements and our analysts will be happy to create a customized report just for you.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770

Release Summary

According to the latest market study released by Technavio, the global non-invasive prenatal testing (NIPT) market is expected to grow at a CAGR of more than 17% during the forecast period.



Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770